A single-centre, multiple-dose trial to investigate the efficacy, tolerability and pharmacokinetics of dalbavancin in volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Jan 2015
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections; Gram-positive infections
- Focus Adverse reactions
- 07 May 2013 New trial record
- 29 Apr 2013 Results were reported in a Durata Therapeutics media release.